Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

@article{Ziske2003PrognosticVO,
  title={Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine},
  author={Carsten G Ziske and C Schlie and Marcus Gorschlueter and Axel G Glasmacher and Ulrich J. M. Mey and John W. Strehl and Tilman Sauerbruch and Ingo G. H. Schmidt-Wolf},
  journal={British Journal of Cancer},
  year={2003},
  volume={89},
  pages={1413 - 1417}
}
Serum carbohydrate antigen 19-9 (CA 19-9) has been identified as a useful tumour marker for diagnosis of exocrine pancreatic carcinoma, but its value for evaluating the response to chemotherapy with gemcitabine is not clear. Tumour regression in pancreatic carcinoma is hard to determine due to massive desmoplastic tissue. Furthermore, objective tumour response does not automatically transcribe into better survival. Therefore, clinical benefit response, a composed parameter consisting of factors… CONTINUE READING
66 Citations
25 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Tumor antigens in pancreatic cancer

  • C Rollhauser, W Steinberg
  • Pancreatic Cancer. Towata, NJ: Humana
  • 1998
3 Excerpts

Similar Papers

Loading similar papers…